Goldman Sachs Starts WuXi PharmaTech (WX) at Buy, Adds to Conviction Buy List
More News related to WX
- WuXi PharmaTech (WX) Posts Q3 non-GAAP EPS of $0.24, Tops by 9c
- WuXi PharmaTech Announces Third-Quarter 2009 Results
- Trading Radar for 11/17: Home Depot (HD), Saks (SKS), Target (TGT), Autodesk (ADSK), La-Z-Boy (LZB) Report
- Credit Suisse Downgrades WuXi PharmaTech (WX) to Neutral
- WuXi AppTec Receives 2009 Schering-Plough Excellence Award
Goldman Sachs initiates coverage on WuXi PharmaTech Inc. (NYSE: WX) with a Buy rating and $15.63 price target and added the stock to their Conviction Buy List.
The firm sees earnings CAGR of 28% for 2009E-2011E and expects WuXi to register above-peer-average operating and net margins of 20% and 17% in 2011E.
Catalysts the analyst cited included: scale, attractive outsourcing location, and business model.
Real-Time Market Moving News Two-Weeks FREE http://www.streetinsider.com/premium_content.php
Related Categories
New CoverageTrader Talk
Stocks Mentioned
-0.11Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
